Targeting the immune system in the treatment of non-small-cell lung cancer

Medicine and Dentistry

• Malignant Neoplasm 100%
• Immunotherapy 100%
• Non Small Cell Lung Cancer 100%
• Immune System 100%
• Cytotoxic Agent 100%
• Therapeutic Vaccine 100%
• Treatment of Non-Small Cell Lung Cancer 100%
• Disease 50%
• Anticarcinogen 50%
• Systemic Therapy 50%
• CTLA-4 50%
• Clinical Endpoint 50%

Keyphrases

• Non-small Cell Lung Cancer (NSCLC) 100%
• Immune System 100%
• Therapeutic Vaccine 50%
• Clinical Response 50%
• Cytotoxic Agents 50%
• Checkpoint Inhibitors 50%
• Improved Outcomes 25%
• Cancer Mortality 25%
• Most Common Cause 25%
• Antineoplastic Agents 25%
• Phase II Study 25%
• Cancer-specific 25%
• Attendants 25%
• Cancer Causes 25%
• Clinical Endpoints 25%
• Immune Therapy 25%
• Systemic Toxicity 25%
• Systemic Therapy 25%
• Synergistic Effect 25%
• Cytotoxic T-lymphocyte antigen-4 (CTLA-4) 25%
• Molecular Agents 25%
• Programmed death-1 Pathway 25%
• New Trial 25%
• Aberrancy 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Non Small Cell Lung Cancer 100%
• Malignant Neoplasm 50%
• Therapeutic Vaccine 50%
• Immunotherapy 50%
• Cytotoxic Agent 50%
• Disease 25%
• Anticarcinogen 25%
• Cytotoxic T Lymphocyte Antigen 4 25%